VAPAWAY.EU - Research and education on VAP prevention

Login

Agenda

9 - 12 March 2010

ISICEM International Symposium on Intensive Care and Emergency Medicine - Brussels (Belgium)

ISICEM

9 -11 June 2010

EACTA European Association of Cardiothoracic Anaesthesiologists - Edinburgh (UK)

EACTA

12-15 June 2010

ESA European Society of Anaesthesiology - Helsinki (Finland)

ESA

18-22 September 2010

ERS European Respiratory Society - Barcellona (Spain)

ERS

9 -13 October 2010

ESICM European Society of Intensive Care Medicine - Barcellona (Spain)

ESICM

> International events

> Local events

Treatment

EFFECT OF VANCOMYCIN PLUS RIFAMPICIN IN THE TREATMENT OF NOSOCOMIAL METHICILLIN RESISTANT STAPHYLOCO
ULTRASOUND ASSESMENT OF ANTIBIOTIC-INDUCED PULMONARY REAERATION IN VAP
NON-ADHERENCE TO GUIDELINES:AN AVOIDABLE CAUSE OF FAILURE OF EMPIRICAL ANTIMICROBIAL THERAPY IN THE
A COMPARISON OF LINEZOLID WITH GLYCOPEPTIDES IN SEVERE MRSA PNEUMONIA
NEBULIZED CEFTAZIDIME IN EXPERIMENTAL PNEUMONIA CAUSED BY PARTIALLY RESISTANT PSEUDOMONAS AERUGINOSA
AEROSOLIZED ANTIBIOTICS IN CRITICALLY ILL VENTILATED PATIENTS
PHARMACODYNAMIC PROFILE OF TIGECYCLINE AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN A EXPE
PHARMACOKINETICS AND LUNG DELIVERY OF PDDS AEROSOLIZED AMIKACIN (NKTR-061) IN INTUBATED AND MECHANIC
PROCALCITONIN FOR REDUCED ANTIBIOTIC EXPOSURE IN VAP: A RANDOMISED STUDY
META-ANLYSIS OF DORIPENEM VS COMPARATORS IN PATIENTS WITH PSEUDOMONAS INFECTIONS ENROLLED IN FOUR PH
ADJUNCTIVE AEROSOLIZRD ANTIBIOTICS FOR TREATMENT OF VAP
DURATION OF ANTIBIOTIC THERAPY FOR VAP IN BURN PATIENTS
TREATMENT OPTIONS FOR NOSOCOMIAL PNEUMONIA DUE TO MRSA
EFFICACY OF INTRAVENOUS INFUSION OF DORIPENEM
SAFETY OF INTRAVENOUS INFUSION OF DORIPENEM
LIKELIHOOD OF INADEQUATE TREATMENT: A NOVEL APPROACH TO EVALUATING DRUG-RESISTANCE PATTERNS
CEFTOBIPROLE:A NEW BOARD SPECTRUM CEPHALOSPORIN
ICLAPRIM,A NOVEL DIAMINOPYRIMIDINE FOR THE TREATMENT OF RESISTANT GRAM-POSITIVE INFECTIONS
DORIPENEM:POSITION IN CLINICAL PRACTICE
CURBING RESISTANCE DEVELOPMENT: MAXIMIZING THE UTILITY OF AVAILABLE AGENTS
VENTILATOR ASSOCIATED PNEUMONIA: AN OVERVIEW
PHARMACODYNAMIC EVALUATION OF TIGECYCLINE ACINETOBACTER BAUMANNII IN A MURINE PNEUMONIA MODEL
INHALED COLISTIN AS MONOTHERAPY FOR MULTIDRUG-RESISTANT GRAM NOSOCOMIAL PNEUMONIA: A CASE SERIES
CLINICAL CURE OF VAP TREATED WITH PIPERACILLIN/TAZOBACTAM ADMINISTERED BY CONTINUOUS OR INTERMITTENT
DOES DE-ESCALATION OF ANTIBIOTIC THERAPY FOR VAP AFFECT THE LIKELIHOOD OF RECCURRENT PNEUMONIA OR MO

<< Start < Prev 1 2 3 Next > End >>
Results 1 - 25 of 67

Cost ( 13 items )
Prevention ( 101 items )
Diagnosis ( 38 items )
Etiology ( 26 items )
Pathophysiology ( 8 items )
Epidemiology: Risk and prognosis factors ( 38 items )
EPIDEMIOLOGY

[ Back ]

Members

Select and watch
from the following webinars

Partner

VAPAWAY is proudly supported by Covidien.